Berufsgenossenschaftliches Universitaetsklinikum Bergmannsheil gGmbH
- Address
- Buerkle De La Camp-Platz 1, Wiemelhausen, 44789 Bochum, Germany
Neuromuscular and Immune-Mediated Disease Research
At Berufsgenossenschaftliches Universitaetsklinikum Bergmannsheil gGmbH, clinical research in immune system diseases and nervous system diseases focuses on generalized myasthenia gravis and related neuromuscular weakness. These studies are designed to assess whether new treatments can better reduce symptoms and improve daily functioning for people living with this chronic condition.
- Generalized myasthenia gravis
- Immune system diseases
- Nervous system diseases
- Testing new therapies for symptom control and daily activity improvement
Research at the site includes comparisons of emerging treatment options and efforts to improve care for patients who need better long-term disease control.
Burn Care and Skin Regeneration
Clinical trials in skin and connective tissue diseases at the University Medical Center address deep partial and full-thickness burns. The main goal is to evaluate whether advanced skin repair approaches can support wound closure, limit scarring, and improve recovery after severe burn injury.
- Deep partial and full-thickness burns
- Skin and connective tissue diseases
- Improving wound healing and reducing scar formation
- Evaluating innovative skin replacement strategies
This area of research reflects a strong interest in restoring skin function and improving outcomes after complex trauma.
Metabolic and Hormonal Health
Trials in nutritional and metabolic diseases and hormonal diseases are examining overweight or obesity, type 2 diabetes, and polycystic ovary syndrome. The research aims to test whether new treatment strategies can improve metabolic control and help restore hormonal balance, especially in people affected by obesity-related reproductive problems.
- Overweight or obesity
- Type 2 diabetes
- Polycystic ovary syndrome
- Hormonal and metabolic disease management
These studies combine metabolic and reproductive health research to explore better ways to support patients with interconnected chronic conditions.
Cardiovascular Risk and Heart Disease
Research in cardiovascular diseases at this site includes studies in people with hypertension, cardiovascular disease, and diabetes-related heart risk. The trials are intended to determine whether new treatment combinations can reduce serious cardiac events and improve protection for patients with multiple cardiovascular risk factors.
- Hypertension
- Cardiovascular disease
- Type 2 diabetes with heart risk
- Evaluating treatment effectiveness for preventing major heart complications
This work highlights an emphasis on lowering the burden of heart disease in patients with complex metabolic and vascular conditions.
Traumatic Brain Injury Research
Clinical trials in nervous system diseases also include subacute moderate to severe traumatic brain injury. The purpose of this research is to examine whether new intranasal treatment approaches are safe, well tolerated, and potentially helpful in supporting recovery after brain injury.
- Subacute moderate to severe traumatic brain injury
- Nervous system diseases
- Assessing safety and tolerability of a new treatment approach
- Exploring recovery support after brain injury
This area adds to the site’s broader focus on neurological care and rehabilitation-related innovation.
Autoimmune Neurology and Targeted Therapy Comparison
Another key theme at Bergmannsheil is the study of generalized myasthenia gravis through direct comparisons of advanced immune-targeted therapies. The research is aimed at identifying which treatment may offer better symptom relief and overall benefit for patients beginning specialized care.
- Generalized myasthenia gravis
- Immune system diseases
- Comparing effectiveness of targeted treatments
- Improving options for patients starting new therapy
These investigations support more personalized treatment decisions in a difficult-to-manage autoimmune neuromuscular disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 8 therapeutic areas and 15 of 41 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
- 1Alkermes Inc.2active
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Apurano Pharmaceuticals GmbH4trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Berufsgenossenschaftliches Universitaetsklinikum Bergmannsheil gGmbH
lock Showing 1 of 14 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Nipocalimab vs Efgartigimod in a Randomized, Open-label, Phase 3b, Interventional Trial Including Within Class Switching From Efgartigimod to Nipocalimab | Janssen Cilag International | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 41 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adezunap | 4 | Unknown | 2023-11-02 | 2023-11-02 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.